Nasdaq

Clearside Biomedical Details Phase 3 Program for CLS-AX in Wet AMD Following Positive FDA Meeting

Receipt of formal meeting minutes from the FDA confirming key elements for two proposed Phase 3 pivotal trials indicates regulatory progress and alignment with the FDA. Positive outcome of the ...
Nasdaq

Clearside Biomedical Highlights CLS-AX Sub-Group Analyses from ODYSSEY Wet AMD Trial at Upcoming Conferences

Clearside Biomedical announces upcoming presentations on CLS-AX sub-group analyses from the ODYSSEY Wet AMD trial at various conferences. Clearside Biomedical, Inc. announced upcoming presentations ...
The New York Times

Argentina’s Leader Takes Ax to Program That Drove Down Teen Pregnancy

Argentina has been known as one of Latin America’s most socially progressive countries. But President Javier Milei’s austerity measures have cut programs aimed at helping women. Argentina has been ...
Seeking Alpha

Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program

Clearside’s patent protected, proprietary suprachoroidal space (SCS ®) injection treatment approach offers unprecedented access to the back of the eye, where sight-threatening disease often occurs.
Seeking Alpha

Clearside Biomedical’s Lead Clinical Program CLS-AX in Wet AMD and Suprachoroidal Delivery Platform Highlighted at the 2025 Wet AMD & Diabetic Eye Disease Summit

Summary: This presentation compared the benefits of TKIs in wet AMD management, focusing on pan-VEGF receptors blockage and extended drug delivery while acknowledging the limitations of current ...
WLRN

Argentina’s leader takes ax to program that drove down teen pregnancy

BUENOS AIRES, Argentina — For three years, Silvia Alanis visited high schools in a small town in northern Argentina, teaching sex education and providing teenagers with birth control as part of a ...
Business Insider

Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program

- Upcoming Presentations at Angiogenesis and Macula Society Conferences to Feature CLS-AX Sub-Group Analyses from ODYSSEY Wet AMD Trial - - CLS-AX Targets Flexible Dosing of Biologics with Duration of ...
WRIC

Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program

ALPHARETTA, Ga., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the ...